- Posts:
- 0 (0 per day)
- Age:
- N/A
- Date Registered:
- May 05, 2024, 12:04:49 PM
- Local Time:
- May 18, 2024, 09:27:12 PM
- Last Active:
- May 05, 2024, 01:51:00 PM
Signature:
3%/8.6% and also One.2%/6.7%, correspondingly. These outcomes illustrate the strength of ranibizumab within treatment-naïve CRVO patients from Y1